A meta-analysis finds few relevant studies, but they indicate some efficacy.
Despite the high prevalence of depression among patients with neurological diseases, there are few randomized controlled studies of antidepressant therapy in such patients. These authors performed a comprehensive analysis of placebo-controlled studies of antidepressants for treating depression (including major depression, dysthymia, and adjustment disorder) in patients with neurological disorders.
Included studies had to have used validated rating scales to assess response. The investigators assessed 68 studies for eligibility and included only 18 in the meta-analysis (stroke, 9; Parkinson disease, 6; multiple sclerosis, 2; traumatic brain injury, 1). The primary endpoint was response at 6 to 8 weeks; response at three other time points, qua…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)